580 related articles for article (PubMed ID: 30326885)
1. Characterization of recombinant OspA in two different Borrelia vaccines with respect to immunological response and its relationship to functional parameters.
Grosenbaugh DA; De Luca K; Durand PY; Feilmeier B; DeWitt K; Sigoillot-Claude C; Sajous ML; Day MJ; David F
BMC Vet Res; 2018 Oct; 14(1):312. PubMed ID: 30326885
[TBL] [Abstract][Full Text] [Related]
2. Immunization with a recombinant subunit OspA vaccine markedly impacts the rate of newly acquired Borrelia burgdorferi infections in client-owned dogs living in a coastal community in Maine, USA.
Eschner AK; Mugnai K
Parasit Vectors; 2015 Feb; 8():92. PubMed ID: 25890386
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of antibody responses to outer surface protein (Osp)A and OspC in dogs vaccinated with Lyme disease vaccines.
Camire AC; Hatke AL; King VL; Millership J; Ritter DM; Sobell N; Weber A; Marconi RT
Vet J; 2021 Jul; 273():105676. PubMed ID: 34148599
[TBL] [Abstract][Full Text] [Related]
4. Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease.
LaFleur RL; Dant JC; Wasmoen TL; Callister SM; Jobe DA; Lovrich SD; Warner TF; Abdelmagid O; Schell RF
Clin Vaccine Immunol; 2009 Feb; 16(2):253-9. PubMed ID: 19052162
[TBL] [Abstract][Full Text] [Related]
5. Demonstration of the ability of a canine Lyme vaccine to reduce the incidence of histological synovial lesions following experimentally-induced canine Lyme borreliosis.
Grosenbaugh DA; Rissi DR; Krimer PM
Vet Immunol Immunopathol; 2016 Nov; 180():29-33. PubMed ID: 27692092
[TBL] [Abstract][Full Text] [Related]
6. Vaccination of horses with Lyme vaccines for dogs induces short-lasting antibody responses.
Guarino C; Asbie S; Rohde J; Glaser A; Wagner B
Vaccine; 2017 Jul; 35(33):4140-4147. PubMed ID: 28668566
[TBL] [Abstract][Full Text] [Related]
7. A fluorescent bead-based multiplex assay for the simultaneous detection of antibodies to B. burgdorferi outer surface proteins in canine serum.
Wagner B; Freer H; Rollins A; Erb HN
Vet Immunol Immunopathol; 2011 Apr; 140(3-4):190-8. PubMed ID: 21208663
[TBL] [Abstract][Full Text] [Related]
8. Protection against tick-transmitted Lyme disease in dogs vaccinated with a multiantigenic vaccine.
Straubinger RK; Dharma Rao T; Davidson E; Summers BA; Jacobson RH; Frey AB
Vaccine; 2001 Oct; 20(1-2):181-93. PubMed ID: 11567763
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of a nonadjuvanted, outer surface protein A, recombinant vaccine in dogs after challenge by ticks naturally infected with Borrelia burgdorferi.
Conlon JA; Mather TN; Tanner P; Gallo G; Jacobson RH
Vet Ther; 2000; 1(2):96-107. PubMed ID: 19757556
[TBL] [Abstract][Full Text] [Related]
10. Development of a multiplex assay for the detection of antibodies to Borrelia burgdorferi in horses and its validation using Bayesian and conventional statistical methods.
Wagner B; Freer H; Rollins A; Erb HN; Lu Z; Gröhn Y
Vet Immunol Immunopathol; 2011 Dec; 144(3-4):374-81. PubMed ID: 21890217
[TBL] [Abstract][Full Text] [Related]
11. Safety, immunogenicity, and efficacy of Borrelia burgdorferi outer surface protein A (OspA) vaccine: A meta-analysis.
Zhao H; Bao FF; Liu A
J Infect Dev Ctries; 2017 Jan; 11(1):1-9. PubMed ID: 28141584
[TBL] [Abstract][Full Text] [Related]
12. Characterization and optimization of a novel vaccine for protection against Lyme borreliosis.
Comstedt P; Hanner M; Schüler W; Meinke A; Schlegl R; Lundberg U
Vaccine; 2015 Nov; 33(44):5982-8. PubMed ID: 26277070
[TBL] [Abstract][Full Text] [Related]
13. Identification of a defined linear epitope in the OspA protein of the Lyme disease spirochetes that elicits bactericidal antibody responses: Implications for vaccine development.
Izac JR; Oliver LD; Earnhart CG; Marconi RT
Vaccine; 2017 May; 35(24):3178-3185. PubMed ID: 28479174
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with the ospA- and ospB-Negative Borrelia burgdorferi Strain 50772 Provides Significant Protection against Canine Lyme Disease.
LaFleur RL; Callister SM; Dant JC; Wasmoen TL; Jobe DA; Lovrich SD
Clin Vaccine Immunol; 2015 Jul; 22(7):836-9. PubMed ID: 25972405
[TBL] [Abstract][Full Text] [Related]
15. Enhanced Protective Immunogenicity of Homodimeric Borrelia burgdorferi Outer Surface Protein C.
Edmondson DG; Prabhakaran S; Norris SJ; Ullmann AJ; Piesman J; Dolan M; Probst C; Radzimski C; Stöcker W; Komorowski L
Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27733423
[TBL] [Abstract][Full Text] [Related]
16. Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA.
Koide S; Yang X; Huang X; Dunn JJ; Luft BJ
J Mol Biol; 2005 Jul; 350(2):290-9. PubMed ID: 15935380
[TBL] [Abstract][Full Text] [Related]
17. DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but Not for resolution of Lyme disease.
Wallich R; Siebers A; Jahraus O; Brenner C; Stehle T; Simon MM
Infect Immun; 2001 Apr; 69(4):2130-6. PubMed ID: 11254567
[TBL] [Abstract][Full Text] [Related]
18. Tick-Tattoo: DNA Vaccination Against
Klouwens MJ; Trentelman JJA; Wagemakers A; Ersoz JI; Bins AD; Hovius JW
Front Immunol; 2021; 12():615011. PubMed ID: 33717102
[TBL] [Abstract][Full Text] [Related]
19. Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs.
Scheckelhoff MR; Telford SR; Hu LT
Vaccine; 2006 Mar; 24(11):1949-57. PubMed ID: 16300863
[TBL] [Abstract][Full Text] [Related]
20. Resolution of experimental and tick-borne Borrelia burgdorferi infection in mice by passive, but not active immunization using recombinant OspC.
Zhong W; Gern L; Stehle T; Museteanu C; Kramer M; Wallich R; Simon MM
Eur J Immunol; 1999 Mar; 29(3):946-57. PubMed ID: 10092099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
